Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* HIV-1 infection~* Lumbar spine DEXA scan confirming decreased BMD within 90 days prior to study entry~* CD4 cell count 100 cells/mm3 or more within 30 days prior to study entry~* Stable antiretroviral regimen for at least 12 weeks prior to study entry~* No plans to alter antiretroviral therapy or to initiate structured/strategic treatment interruptions~* No plans to significantly alter exercise habits or diet for the duration of the study~* Documentation of two consecutive measurements of viral load of 5000 copies/ml or less within 90 days prior to study entry, with at least one of the two values obtained within 30 days prior to study entry~* Willing to use acceptable methods of contraception~* For women with the absence of menses for at least 6 months, serum prolactin level in the normal range within 60 days prior to study entry~* For women taking estrogen therapy, stable estrogen regimen for at least 24 weeks prior to study entry, with no plan to change estrogen dose for the duration of the study~* Serum calcium between 8 mg/dl and 11 mg/dl within 30 days prior to study entry~Exclusion Criteria~* Men with untreated low total serum testosterone levels within 60 days prior to study entry, or men with plans to initiate testosterone replacement during the study~* Cannot receive vitamin D or calcium supplements~* Daily vitamin or dietary supplements that include 10,000 IU or greater of vitamin A within 90 days prior to study entry~* Hyperparathyroidism, vitamin D deficiency, or oral thrush within 60 days prior to study entry~* Any current or past conditions that predispose to disorders involving the esophagus. Participants with a history of mild or controlled reflux may be enrolled.~* Esophagitis within 6 months prior to study entry~* Pregnant or breastfeeding~* Paget's disease~* Spinal fracture (thoracic or lumbar spine) within 60 days prior to study entry~* Atraumatic bone fracture at any time since 18 years of age~* Spinal fracture at any time in the past~* Inability to stand or sit upright for at least 30 minutes~* Use of systemic glucocorticoids for a cumulative duration of longer than 4 weeks within 6 months immediately prior to study entry~* Use of medications for treatment of osteoporosis within 12 months prior to study entry~* Allergy/hypersensitivity to any component of alendronate, the components of the tablet, or bisphosphonate compounds~* Active drug or alcohol dependence which, in the opinion of the investigator, would interfere with adherence to study requirements or would endanger the patient's health while on study~* Hospitalization for alcohol-related liver disease at any time in the past~* Current use of systemic cytotoxic chemotherapy~* Acute illness within 30 days prior to study entry which, in the opinion of the investigator, would interfere with participation in the study~* History of hepatitis C virus infection~* For participants using anabolic steroids, use of steroids for less than 6 months prior to entry or plans to change current regimen during the course of the study; if a steroid regimen has been discontinued, it must have been discontinued at least 6 months prior to entry

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete